Results 51 to 60 of about 284,151 (314)
Molecular Oncology, EarlyView.This study investigates gene expression differences between two major pediatric acute lymphoblastic leukemia (ALL) subtypes, B‐cell precursor ALL, and T‐cell ALL, using a data‐driven approach consisting of biostatistics and machine learning methods. Following analysis of a discovery dataset, we find a set of 14 expression markers differentiating the ...
Mona Nourbakhsh +8 more
wiley +1 more source
Comprehensive review of fetal adenocarcinoma of the lung
Lung Cancer: Targets and Therapy, 2018 Luisa María Ricaurte,1 Oscar Arrieta,2 Zyanya Lucia Zatarain-Barrón,2 Andrés F Cardona1,3 1Foundation for Clinical and Applied Cancer Research – FICMAC, Bogotá, Colombia; 2Thoracic Oncology Unit, National Cancer ...
Ricaurte LM +3 more
doaj
Translational Oncology, 2022 Objectives: ARNTL2, as a circadian transcription factor, has been recently proposed to play an important role in a variety of tumors. however, the role of ARNTL2 in lung carcinogenesis and progression remains unclear.
Huan Zhang +10 more
doaj
Journal of Medical Case Reports, 2019 Background Endothelial growth factor receptor (EGFR) mutations are an essential driver of personalized therapy for patients with lung cancer and are detected in approximately 15% of Caucasian and 50% of Asian patients.
Juan C. Falla-Martinez +5 more
doaj +1 more source
TENET 2.0: Identification of key transcriptional regulators and enhancers in lung adenocarcinoma.
PLoS Genetics, 2020 Lung cancer is the leading cause of cancer-related death and lung adenocarcinoma is its most common subtype. Although genetic alterations have been identified as drivers in subsets of lung adenocarcinoma, they do not fully explain tumor development ...
Daniel J Mullen +8 more
doaj +1 more source
Molecular Oncology, EarlyView.This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau +9 more
wiley +1 more source
A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner
Molecular Oncology, EarlyView.We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp +13 more
wiley +1 more source
p40 Immunohistochemistry Is an Excellent Marker in Primary Lung Squamous Cell Carcinoma [PDF]
Journal of Pathology and Translational Medicine, 2018 Background Lung cancer is the third most common cancer worldwide. With major advances in the molecular testing of lung cancers and the introduction of targeted therapies, the distinction between adenocarcinoma and squamous cell carcinoma as well as ...
Khairunisa Ahmad Affandi +3 more
doaj +1 more source
Molecular Oncology, EarlyView.C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald +18 more
wiley +1 more source
High-grade Fetal Adenocarcinoma of the Lung: A Case Report
Chinese Journal of Lung Cancer, 2019 Fetal adenocarcinoma of the lung (FLAC) is an extremely rare subtype of lung cancer, accounting for only 0.1% to 0.5% of primary pulmonary malignancy.
Chuan HUANG +8 more
doaj +1 more source